RESOURCES DESIGNED
TO HELP PATIENTS

Exclusively at Walgreens and other participating independent pharmacies.

GET MORE INFORMATION
ON PATIENT SAVINGS

DOWNLOAD NOW
savings icons

Discounted pricing is available for eligible uninsured patients.* Ask a VYZULTA representative for more information about additional savings options.

*Terms, conditions, and limitations apply. See eligibility criteria and terms and conditions at www.BauschAccessProgram.com.

EASY ACCESS FOR MILLIONS OF PATIENTS WITH
COMMERCIAL INSURANCE AND MEDICARE PART D

UNRESTRICTED ACCESS FOR

75million
21million

NO STEP EDITS OR PRIOR AUTHORIZATIONS

MMIT data, March 2021.

A PA may be required for some claims. To date, the majority of prior authorizations submitted for VYZULTA through PARx have been approved.

Visit parxsolutions.com or call (866) 725-7279. Source: PARx Solutions, January 2021.

 

ACCESS SUPPORT RESOURCES

request icon

NEED TO REQUEST A TIER EXCEPTION?

letter icon

WRITING A LETTER OF MEDICAL NECESSITY?

support icon

SUPPORT THROUGH PARx CALL (866) 725-7279 OR VISIT ONLINE

Eye care professionals talk about why getting patients access to VYZULTA is worth it.

CONVENIENT ONCE-NIGHTLY DOSING1

eye drop icon

One drop in the conjunctival sac of the affected eye(s) once nightly1

clock icon

Administer other topical ophthalmic intraocular pressure drugs at least 5 minutes apart1

 

 

eye drop icon

Can be stored at room temperature for up to 8 weeks once opened1

contact lens icon

Remove contact lenses prior to administration. Lenses may be reinserted 15 minutes after administration1

GET A COPY OF THE VYZULTA
PATIENT ADHERENCE FLASH CARD.

Help to reinforce with your patients
the importance of taking VYZULTA
every day as directed


DOWNLOAD NOW
savings flyer
Eye Drop

SIGN UP TO RECEIVE UPDATES AND LEARN MORE ABOUT VYZULTA

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
PLEASE SEE FULL PRESCRIBING INFORMATION >

Reference: 1. VYZULTA Prescribing Information. Bausch & Lomb Incorporated.

SEE MORE

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent